Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial

Claire Falandry, MD; Frédérique Rousseau, MD; Marie-Ange Mouret-Reynier, MD; Fabien Tinquaut, MSc; Domenica Lorusso, MD; Jørn Herrstedt, MD; Aude-Marie Savoye, MD; Laetitia Stefani, MD; Emmanuelle Bourbouloux, MD; Robert Sverdlin, MD; Veronique D’Hondt, MD; Alain Lortholary, MD; Pierre-Emmanuel Brachet, MD; Alain Zannetti, MD; Emmanuelle Malaurie, MD; Laurence Venat-Bouvet, MD; Olivier Trédan, MD; Loïc Mourey, MD; Eric Pujade-Lauraine, MD; Gilles Freyer, MD; for the Groupe d’Investigateurs Nationaux pour l’Étude des Cancers de l’Ovaire et du sein (GINECO)

[1]  Ftlo Bonin-Cecelia,et al.  Phase II: , 2020, The Power of Accountability.

[2]  F. Guyon,et al.  Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, foll , 2019, Journal of gynecology obstetrics and human reproduction.

[3]  H. Donovan,et al.  Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance? , 2019, Gynecologic oncology.

[4]  L. V. van Huis-Tanja,et al.  Treatment decision-making in elderly women with ovarian cancer: an age-based comparison , 2019, International Journal of Gynecologic Cancer.

[5]  A. Gadducci,et al.  Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index , 2017, International Journal of Gynecologic Cancer.

[6]  A. Weaver,et al.  Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer. , 2017, Gynecologic oncology.

[7]  G. Scambia,et al.  Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments , 2017, Aging and disease.

[8]  A. Secord,et al.  Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. , 2017, Gynecologic oncology.

[9]  P. Viens,et al.  Prognostic Factors for Ovarian Epithelial Cancer in the Elderly: A Case-Control Study , 2015, International Journal of Gynecologic Cancer.

[10]  B. Weber,et al.  Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  B. V. van Munster,et al.  Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. , 2012, The Lancet. Oncology.

[12]  Kathleen M. Fairfield,et al.  Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Tinker,et al.  Clinical Trials and Treatment of the Elderly Diagnosed With Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.

[14]  D. Lacombe,et al.  EORTC elderly task force position paper: approach to the older cancer patient. , 2010, European journal of cancer.

[15]  S. Pignata,et al.  A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. , 2008, Critical reviews in oncology/hematology.

[16]  A. Fader,et al.  Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. , 2008, Gynecologic oncology.

[17]  D. Levine,et al.  Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. , 2007, Gynecologic oncology.

[18]  B. Weber,et al.  Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  S. Loibl,et al.  Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  B. Weber,et al.  Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Janssen-Heijnen,et al.  The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. , 2005, Gynecologic oncology.

[22]  A. Neugut,et al.  Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. , 2004, Gynecologic oncology.

[23]  P. DiSilvestro,et al.  Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. , 2002, Gynecologic oncology.

[24]  A. Fishman,et al.  Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. , 2002, Gynecologic oncology.

[25]  I. Tannock,et al.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.

[26]  A. Gadducci,et al.  Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. , 2002, Gynecologic oncology.

[27]  A. Rademaker,et al.  Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .